PRIMARY STUDY

Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy

Key Findings:  This study found that cannabidivarin (CBDV) targets neurotypical and autistic adult brains in mostly the same way, but the individual response to CBDV in the autistic brains was more variable depending on initial glutamate and glutamine levels. This supports further understanding of how CBDV affects the brain, but not necessarily on how it affects the autistic brain.

Type of Study:  Double Blind Human Trial

Study Sample Size:  34

Study Result:  Inconclusive

Study Location(s):  United Kingdom, United States

Year of Pub:  2019


Cannabinoids Studied:  Cannabidivarin (CBDV)

Phytocannabinoid Source:  Not Applicable

Receptors Studied:  TRPA1, TRPV1, TRPV2

Ligands Studied:  GABA, Glutamate

Dosage: CBDV (600 mg)

Route of Administration:  Oral (Ingestion)



Link to study